Core Viewpoint - The market anticipates Opus Genetics, Inc. will report a year-over-year increase in earnings despite lower revenues for the quarter ending September 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus EPS estimate for Opus Genetics is a loss of $0.14 per share, reflecting a year-over-year improvement of +51.7%. Revenues are projected at $2.77 million, down 28.4% from the previous year [3]. - The consensus EPS estimate has been revised down by 4.55% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. - The stock holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [13]. Historical Performance - In the last reported quarter, Opus Genetics was expected to post a loss of $0.25 per share but actually reported a loss of -$0.12, achieving a surprise of +52.00%. Over the last four quarters, the company has beaten consensus EPS estimates three times [14][15]. Industry Context - Certara, Inc., a peer in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings of $0.11 per share for the same quarter, indicating a year-over-year decline of -15.4%. Its revenue is projected to be $105.22 million, up 11% from the previous year [19][20]. The consensus EPS estimate for Certara has been revised up by 77.3% in the last 30 days, but a lower Most Accurate Estimate results in an Earnings ESP of -4.76% [20][21].
Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release